A Review of Secukinumab in Psoriasis Treatment

Berg, Scott H; Balogh, Esther A.; Ghamrawi, Rima I.; Feldman, Steven R.

doi:10.2217/imt-2020-0195

Cited by 14 publications

(10 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…2 Psoriasis vulgaris is the most common type, with 90% of total psoriasis patients. 15 In this study, the number of psoriasis patients was 845, 9.9% of patients at the DV Clinic of therapy. Secukinumab can also be given to psoriasis patients with special conditions, such as there are extensive lesions on the scalp that do not respond to topical drugs, involvement of visible areas (such as hands and face), and resistance to topical drugs.…”

Section: Discussionmentioning

confidence: 69%

Secukinumab Therapy on Psoriasis at Dr. Mohammad Hoesin General Hospital Palembang

et al. 2022

View full text Add to dashboard Cite

Background: Psoriasis is a chronic inflammatory skin disease mediated by T lymphocytes. IL-17 or IL-22 plays an important role in the chronic inflammatory process. Secukinumab is an effective biological agent therapy with a molecular target, IL-17A. This study aimed to describe PASI improvement and safety of using secukinumab in psoriasis patients at the Dermatology and Venereology Clinic Dr. Mohammad Hoesin General Hospital Palembang. Methods: This study was a retrospective, descriptive-analytic study. The inclusion criteria of this study were all medical record data of patients diagnosed with cutaneous psoriasis through anamnesis, clinical and histopathology examination, treated with secukinumab from January 2018 to December 2020. Results: Psoriasis patients with secukinumab therapy were 15 people. The number of male patients was 8 people, the mean age (+ SD) was 40.4, + 12.34 years, and the age range was 19-64 years. A family history of psoriasis was present in 2 patients (13.4%). Psoriasis vulgaris was the most prevalent type of psoriasis and was treated with secukinumab in 8 patients (53.3%). Another type was pustular psoriasis (20%) and erythrodermic psoriasis (26,7%). The triggers of exacerbations obtained in this study include occupation, hypertension, diabetes mellitus, obesity, smoking, and infections. PASI 75 was achieved by 13 patients (86.7%) at week 12, and all patients achieved DLQI<5. There were no adverse events during the use of secukinumab. Conclusion: The improvement of PASI and DLQI scores were achieved at week 12 in accordance with previous studies. Risk factors do not reduce the therapeutic effect of secukinumab in achieving PASI 75.

show abstract

Section: Discussionmentioning

confidence: 69%

Secukinumab Therapy on Psoriasis at Dr. Mohammad Hoesin General Hospital Palembang

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Keratinocytes themselves, when stimulated, also synthesize many cytokines that can induce epidermal hyperplasia (autocrine growth factors) or neoangiogenesis (paracrine growth factors), resulting in worsening of EP and initiating a reverberating loop that perpetuates pro-proliferative and proinflammatory stimuli (9). Consistently, blocking IL-17A results in an improvement of psoriasis lesions, suggesting a key role in the pathogenesis of EP (8). Currently, one anti-IL-17A biological agent is approved for the treatment of plaque psoriasis, secukinumab, a monoclonal antibody that targets IL-17A (10).…”

Section: Secukinumab: Drug Description and Focus On The Treatment Of Epmentioning

confidence: 95%

“…Some environmental triggers, such as physical trauma, drugs, or infections, release proinflammatory cytokines, including IL-23 and TNF-α. Differentiation of T helper into Th17 cells and the release of cytokines, such as IL-17, promote keratinocyte proliferation, which, in the setting of EP, also release additional ILs and chemokines ( 8 ). The homodimeric glycoprotein IL-17A belongs to the IL-17 family and through its receptor complex IL-17RA/IL-17RC binds to keratinocytes, dendritic cells, dermal fibroblast, and endothelial cells.…”

Section: Introductionmentioning

confidence: 99%

Erythrodermic psoriasis and palmoplantar hyperkeratosis successfully treated with secukinumab: a case report

Carriero

2022

dti

View full text Add to dashboard Cite

Erythrodermic psoriasis (EP) is a rare and severe form of psoriasis that affects 1 to 2.25% of patients, increasing mortality risk. To date, very few therapies have been approved for the treatment of this condition. Recently, biological therapies which specifically target inflammatory cytokines have improved the management and treatment of EP. Secukinumab, a human monoclonal antibody that specifically targets interleukin-17A (IL-17A), has been shown to be beneficial in different psoriasis settings. We report the case of a 72-year-old man affected by persistent EP and severe palmoplantar hyperkeratosis whose condition was not resolved after two rounds of treatment with prednisone and therapy with cyclosporine. Treatment with secukinumab significantly improved the symptoms of palmoplantar hyperkeratosis as early as the first weeks, with a decrease of Psoriasis Area Severity Index (PASI) score from 60 to 10, showing almost complete remission after 1 month. Consistent with the current literature, secukinumab treatment showed promising and encouraging clinical outcomes in the treatment of the patient’s EP. However, more studies are needed to clarify the IL-17-dependent mechanism in the pathophysiology of EP.

show abstract

“…Одним из таких препаратов является секукинумабселективный ингибитор IL-17. Секукинумаб показал свою высокую эффективность и удовлетворительный профиль безопасности у взрослых, страдающих псориазом [20][21][22]. В настоящее время более 400 тыс.…”

Section: патогенез псориаза новые возможности таргетного воздействияunclassified

Management of Moderate and Severe Forms of Psoriasis in Children: New Opportunities of Genetically Engineered Biologic Drugs

Namazova-Baranova

Бакулев

Murachkin

et al. 2021

Vopr. sovr. pediatr.

View full text Add to dashboard Cite

The article shows the key role of IL-17 in the psoriasis pathogenesis and the opportunities of its management via monoclonal antibodies product secukinumab. The review of international randomized trials on clinical efficacy and safety of genetically engineered biologic drug secukinumab in children and adolescents with psoriasis is presented. During treatment periods of 12 to 52 weeks, secukinumab has shown high therapeutic efficacy for psoriasis severity and skin lesion areas and has improved quality of life of children and adolescents according to dynamic assessments of PASI, IGA 0/1 mod 2011 indices, CDLQI questionnaire. The safety profile of secukinumab in children is estimated as favorable and comparable to using it in adults.

show abstract

A Review of Secukinumab in Psoriasis Treatment

Cited by 14 publications

References 99 publications

Secukinumab Therapy on Psoriasis at Dr. Mohammad Hoesin General Hospital Palembang

Secukinumab Therapy on Psoriasis at Dr. Mohammad Hoesin General Hospital Palembang

Erythrodermic psoriasis and palmoplantar hyperkeratosis successfully treated with secukinumab: a case report

Management of Moderate and Severe Forms of Psoriasis in Children: New Opportunities of Genetically Engineered Biologic Drugs

Contact Info

Product

Resources

About